A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study

Jin Nakagawa, Yoshinobu Koyama, Atsushi Kawakami, Yukitaka Ueki, Hiroshi Tsukamoto, Takahiko Horiuchi, Shuji Nagano, Ayumi Uchino, Toshiyuki Ota, Mitsuteru Akahoshi and Koichi Akashi

Abstract

Background: Currently, although several categories of biological disease-modifying antirheumatic drugs (bDMARDs) are available, there are few data informing selection of initial treatment for individual patients with rheumatoid arthritis (RA). Therefore, tumor necrosis factor inhibitor (TNF-i) and tocilizumab (TCZ) are treated as equivalent treatments in the recent disease management recommendations. We focused on two anticytokine therapies, TCZ and TNF-i, and aimed to develop a scoring system that predicts a better treatment for each RA patient before starting an IL-6 or a TNF-i.

Methods: The expression of IL-6 and TNF-α mRNA in peripheral blood from 45 newly diagnosed RA patients was measured by DNA microarrays to evaluate cytokine activation. Next, laboratory indices immediately before commencing treatment and disease activity score improvement ratio after 6 months in 98 patients treated with TCZ or TNF-i were retrospectively analyzed. Some indices correlated with TCZ efficacy were selected and their cutoff values were defined by receiver operating characteristic (ROC) analysis to develop a scoring system to discriminate between individuals more likely to respond to TCZ or TNF-i. The validity of the scoring system was verified in these 98 patients and an additional 228 patients.

Results: There was significant inverse correlation between the expression of IL-6 and TNF-α mRNA in newly diagnosed RA patients. The analysis of 98 patients revealed significant correlation between TCZ efficacy and platelet counts, hemoglobin, aspartate aminotransferase, and alanine aminotransferase; in contrast, there was no similar correlation in the TNF-i group. The cutoff values were defined by ROC analysis to develop a scoring system (1 point/item, maximum of 4 points). A good TCZ response was predicted if the score was ≥2; in contrast, TNF-i seemed to be preferable if the score was ≤1. Similar results were obtained in a validation study of an additional 228 patients. If the case scored ≥3, the good responder rates of TCZ/TNF-i were 75.0%/37.9% (p < 0.01) and the non-responder rates were 3.1%/27.6% (p < 0.01), respectively.

(Continued on next page)
Background
Rheumatoid arthritis (RA) is a chronic inflammatory disease, characteristic of persistent synovitis and destruction of bone and cartilage in multiple joints [1]. Although its etiological causes are still unclear, the efficacy of specific proinflammatory cytokine targets clearly identifies these cytokines as relevant in RA pathogenesis. Since the first report of the tumor necrosis factor-α (TNF-α) inhibitor (TNF-i) infliximab as the first biological disease-modifying antirheumatic drug (bDMARD) for treatment of RA in 1993 [2], bDMARDs, including several TNF-α inhibitors [2–5], tocilizumab (TCZ) as an interleukin 6 (IL-6) inhibitor [6, 7], anakinra as an IL-1 inhibitor [8], abatacept (ABT) as a T cell co-stimulator inhibitor [9], and rituximab as a B cell depleting monoclonal antibody [10], have become available, and innovative progress in RA treatment has been made due to their potent clinical efficacy. Currently, although several categories of bDMARDs are available, the preferable bDMARD for each RA case is not obvious. Therefore, TNF-α, TCZ, and ABT are basically treated as equivalent treatments in the recent disease management recommendations [11, 12]. However, it is occasionally observed that some patients who do not respond to the first biological treatment have a more obvious response to other bDMARDs. To date, many studies that focused on switching bDMARDs have been reported [5, 9, 13–16], and some authors recently suggested that switching to a bDMARD with a different mode of action may be more efficacious than switching to one that targets the same molecule [15, 16]. These studies of bDMARD switching and the aforementioned occasional cases suggest that the dominant inflammatory cytokine that should be targeted may be different in each RA patient.

For the purpose of achieving early remission and efficient medical economics, it is desirable to predict the dominant cytokine that should be inhibited before starting anticytokine therapy. The objective of this study was to develop a scoring system based on common laboratory indices that could discriminate between individuals more likely to respond to either TCZ or a TNF-i.

Methods
Patients
First, 45 newly diagnosed Japanese RA patients were included to estimate the relative expression of IL-6 and TNF-α mRNA in the peripheral blood before therapeutic intervention. Then, another 98 Japanese RA patients receiving TCZ or a TNF-i from 2005 to 2010 at Iizuka Hospital were studied to develop a scoring system that could discriminate between individuals more likely to respond to either TCZ or a TNF-i. We also studied an additional 228 Japanese RA patients for the validation study. They were treated with TCZ or a TNF-i at Kyushu University Hospital, Nagasaki University Hospital, Sasebo-chuo Hospital, Japanese Red Cross Okayama Hospital, and Iizuka Hospital from 2011 to 2014, and the number of patients in each setting was 31, 18, 73, 17, and 89, respectively. All of the patients fulfilled the 1987 classification criteria of the American College of Rheumatology for RA. This study was approved by the ethics committee of Kyushu University Hospital, Nagasaki University Hospital, Sasebo-chuo Hospital, Japanese Red Cross Okayama Hospital, and Iizuka Hospital, and the principles of the Helsinki Declaration were followed throughout the study. The gene expression study in 45 newly diagnosed RA patients was also approved by the ethics committee of Iizuka Hospital and was performed in accordance with the “Ethical Guidelines for Human Genome/Gene Research” published by the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT). Informed consent was obtained from all participants.

Analysis of gene expression level
In order to clarify the signature of gene expression at RA pathogenesis, peripheral whole blood was drawn from the 45 patients who were newly diagnosed and exposed neither to steroids nor to anti-rheumatic drugs. The samples were prepared and subjected to RNA extraction using the PAXgene system (Qiagen, Germantown, MD, USA). Messenger RNA levels were then measured using Agilent whole human genome 60 K (Agilent Technologies, Santa Clara, CA, USA) and the log-transformed raw intensity data were normalized with a quantile algorithm. In order to evaluate the expression balance between IL-6 and TNF-α, correlation was tested between the relative mRNA levels of each gene.

Development of a scoring system that predicts the efficacy of TCZ
Twenty-seven RA patients who were administered TCZ and 71 RA patients who were administered a TNF-i-
(etanercept (ETN): 36 patients, infliximab (IFX): 25 patients, adalimumab (ADA): 10 patients) at Iizuka Hospital from 2005 to 2010 were retrospectively analyzed to investigate the correlation between the efficacy of treatment and the laboratory parameters immediately before commencing treatment. Patients administered conventional DMARDs or patients with previous use of other bDMARDs were included in this analysis. In each group (TCZ group or TNF-i group), disease activity score in 28 joints using erythrocyte sedimentation rate (DAS-ESR) at week 24 and at baseline was used for calculation of the DAS ratio (= DAS-ESR at week 24/DAS-ESR at baseline) as the measure of drug efficacy. Then, correlation was tested between the DAS ratio and each laboratory test result at baseline. In this process, patients with liver dysfunction or renal dysfunction were excluded, and patients with DAS remission at baseline were also excluded. Male hemoglobin (Hb) values were multiplied by 0.88 to correct for the difference between male and female Hb levels, based on the average ratio of male and female Hb levels in similarly aged Japanese people [17]. Several items that were significantly correlated with the DAS ratio in the TCZ group but not in the TNF-i group were selected, and the cut-off values for each item were defined using receiver operating characteristic (ROC) analysis to separate the good responders to TCZ from the moderate responders and non-responders to TCZ. Then, a scoring system to predict the efficacy of TCZ was developed using these cut-off values. The validity of this scoring system was tested by applying this system to the clinical data on the aforementioned 98 patients at Iizuka Hospital.

The validation study of the scoring system in a second set of patients

Another test was performed to validate this scoring system by using the clinical data on 228 patients (TCZ: 129 patients, TNF-i: 99 patients (ETN: 31 patients, IFX: 25 patients, ADA: 26 patients, golimumab (GLM): 13 patients, certolizumab pegol (CZP): 4 patients)). These patients were treated with TCZ or a TNF-i at Kyushu University Hospital, Nagasaki University Hospital, Sasebo-chuo Hospital, Japanese Red Cross Okayama Hospital, and Iizuka Hospital from 2011 to 2014, and the number of patients in each setting was 31, 18, 73, 17, and 89, respectively. Their laboratory tests at baseline were scored by the aforementioned scoring system, and the association between the score and the efficacy of TCZ or a TNF-i was examined.

Statistics

The differences between two groups were analyzed using Student’s t test. If there were a significant difference between the variances of the two samples, the Wilcoxon rank-sum test was applied. Correlation between the IL-6 and TNF-α mRNA expression levels and the DAS ratio and other continuous variables was tested using Spearman’s rank correlation. The differences between the good responder and non-responder rates in the TCZ or TNF-i groups were examined using the chi-squared ($\chi^2$) test. All analyses were performed by JMP statistical software (SAS Institute). $P < 0.05$ was considered statistically significant.

Results

Inverse correlation between IL-6 and TNF-α mRNA expression in RA patients

To study the correlation between IL-6 and TNF-α in RA, we measured the mRNA expression of these cytokines in peripheral blood from 45 newly diagnosed RA patients. This analysis revealed significant inverse correlation between the mRNA expression levels of IL-6 and TNF-α ($R = -0.29$, $p = 0.03$), suggesting that the dominant inflammatory cytokine that should be targeted may be different in each RA patient (Fig. 1).

Development of a scoring system that predicts the efficacy of TCZ

To aid in selecting either TCZ or a TNF-i for the treatment of RA, we aimed to develop a scoring system that reflects the dominant cytokine and predicts the efficacy of medications by analyzing common clinical data.

In this analysis, data on 98 patients treated with TCZ or a TNF-i at Iizuka Hospital from 2005 to 2010 were analyzed.
retrospectively analyzed. There were no significant differences between the backgrounds of patients in the IL-6 inhibitor group and the TNF-i group (Table 1). Among the 27 patients in the TCZ group, 2 patients with liver dysfunction and 2 with renal dysfunction were excluded; thus, 23 patients were included in this analysis. Among the 71 patients in the TNF-i group, in addition to 3 patients with liver dysfunction and 1 with renal dysfunction, 4 patients with DAS remission at baseline were excluded; thus, 63 patients were included in this analysis.

On testing of correlation between the DAS ratio and laboratory data at baseline, there was significant correlation the DAS ratio and platelet count (Plt), Hb, aspartateaminotransferase (AST), and alanineaminotransferase (ALT), specifically in the TCZ group (Table 2). As a result of the analysis, Plt, Hb, AST, and ALT were selected, and the cut-off values were defined by ROC analysis as 381 × 10³/mm³, 11.7 g/dL (male 13.2 g/dL), 16 IU/L, and 15 IU/L, respectively. Then, a scoring system was developed using these four items, and the cut-off values (1 point per item, maximum 4 points) are shown in Table 3.

Then, the 23 cases in the TCZ group and 63 cases in the TNF-i group used for the aforementioned analysis were scored using this scoring system, and the distributions of scores in each drug and each response group were compared using the European League Against Rheumatism (EULAR) response criteria. The comparison revealed that all good responders to TCZ scored 2 or more points, whereas the non-responders to TCZ and 82% of the good responders to TNF-i scored 2 or fewer points. In contrast, if the patients scored 2 or more points, the rates of being a good responder to TCZ and TNF-i were, respectively, 66.7% and 32.5% ($p = 0.01$) (the prior rates in the all of each group were 52.2% and 36.5%, respectively; $p = 0.19$) (Fig. 2). In the same group, the rates of being a non-responder to TCZ or TNF-i were, respectively, 0% and 23.3% ($p = 0.005$) (the prior rates in the all of each group were 4.3% and 23.8%, respectively; $p = 0.02$). These differences became more remarkable in patients with 3 or more points; for these patients, the rates of being a good responder to TCZ or TNF-i were, respectively, 69.2% and 19.0% ($p = 0.003$), and the rates of being a non-responder were, respectively, 0.0% and 28.6% ($p = 0.01$). In contrast, if the score was 1 or less, the rates of being a good responder to TCZ or TNF-i were 0.0% and 45.0% ($p = 0.02$). When good and moderate response to treatment was defined “condition positive” and a score of 2 or more in the TCZ group or a score of 1 or less in the TNF-i group was defined “test positive”, the predictive values were as follows: positive predictive value (PPV): 100.0%, negative predictive value (NPV): 20.0% in TCZ group, and PPV: 71.4%, NPV: 21.4% in the TNF-i group. Thus, this score seemed to supply helpful information on choosing a better treatment. There was also significant correlation between the score and the DAS ratio in the TCZ

| Table 1 | Background data on the original 98 patients from Iizuka hospital and on an additional 228 patients from five other hospitals |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| Patients from Iizuka Hospital, whose data were used to develop the scoring system (n = 98) | Patients from five other hospitals, whose data were used for the validation study (n = 228) |
| **TZC group** | **TNF-i group** | **p value** | **TZC group** | **TNF-i group** | **p value** |
| Number of patients | 27 | 71 | 129 | 99 |
| IFX | 25 | | IFX | 25 |
| ADA | 10 | | ADA | 26 |
| ETN | 36 | | ETN | 31 |
| GLM | 13 | | CZP | 4 |
| Female, n (%) | 24 (88.9%) | 59 (83.1%) | 0.74 | 111 (86.1%) | 75 (75.8%) | 0.05 |
| Age, years (SD) | 60.3 (13.4) | 60.7 (14.1) | 0.76 | 58.5 (14.0) | 63.0 (13.3) | 0.02 |
| TJC (SD) | 10.5 (8.5) | 7.9 (7.1) | 0.20 | 10.4 (8.3) | 6.9 (6.3) | 0.0019 |
| SJC (SD) | 6.4 (5.3) | 5.2 (4.1) | 0.36 | 5.3 (4.8) | 6.3 (4.8) | 0.06 |
| Patient VAS, mm (SD) | 53.6 (29.6) | 57.3 (28.9) | 0.98 | 47.7 (26.9) | 51.3 (27.6) | 0.32 |
| ESR, mm/h (SD) | 47.4 (28.6) | 41.6 (28.8) | 0.18 | 53.4 (37.5) | 40.7 (28.5) | 0.006 |
| CRP, mg/dL (SD) | 2.9 (3.0) | 2.5 (2.4) | 0.34 | 2.5 (3.2) | 3.3 (2.8) | 0.75 |
| DAS28-ESR (SD) | 5.7 (2.6) | 5.2 (2.5) | 0.08 | 5.4 (1.5) | 5.0 (1.3) | 0.06 |

Data on the original 98 patients from Iizuka hospital (2005 to 2010) were used for developing a scoring system and data on the 228 patients from Iizuka hospital (2011 to 2015) and other four hospitals were used for the validation study. Data presented are number of patients or mean unless otherwise noted. TJC tender joint count, SJC swollen joint count, VAS visual analog scale, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS28-ESR disease activity score in 28 joints calculated by using erythrocyte sedimentation rate, TCZ tocilizumab, TNF-i tumor necrosis factor inhibitor, IFX infliximab, ADA adalimumab, ETN etanercept, GLM golimumab, CZP certolizumab pegol
The table for the different tests are all fulfilled.

Each item gives 1 point. The maximum number of points is 4 if the criteria in the table for the different tests are all fulfilled.

**Table 2** Correlation between improvement in the DAS and each laboratory test before treatment

| Laboratory test               | TCZ group | TNF-i group |
|-------------------------------|-----------|-------------|
|                               | R        | p value     | R       | p value     |
| Hemoglobin                    | 0.56     | 0.003       | -0.16   | 0.107       |
| Platelet count                | -0.42    | 0.023       | 0.19    | 0.063       |
| Aspartate aminotransferase    | 0.46     | 0.014       | 0.21    | 0.053       |
| Alanine aminotransferase      | 0.50     | 0.007       | 0.20    | 0.057       |
| Lactate dehydrogenase         | -0.11    | 0.324       | 0.22    | 0.185       |
| Ferritin                      | -0.25    | 0.154       | -0.13   | 0.299       |
| y-Glutamilitranspeptidase     | 0.00     | 0.498       | 0.17    | 0.247       |
| Blood urea nitrogen           | 0.19     | 0.189       | -0.08   | 0.339       |
| Creatinine                    | 0.00     | 0.496       | 0.09    | 0.257       |
| Total protein                 | -0.10    | 0.333       | -0.28   | 0.078       |
| Albumin                       | 0.13     | 0.273       | -0.29   | 0.011       |
| Cholesterol                   | 0.16     | 0.243       | 0.25    | 0.103       |
| Low density lipoprotein       | 0.10     | 0.361       | 0.20    | 0.237       |
| Iron                          | 0.66     | 0.037       | 0.52    | 0.035       |
| Ferritin                      | -0.31    | 0.152       | 0.41    | 0.063       |
| Matrix metalloprotease 3      | -0.13    | 0.283       | 0.16    | 0.151       |
| Serum albumin A               | -0.32    | 0.079       | 0.13    | 0.246       |
| Rheumatoid factor             | -0.06    | 0.403       | 0.18    | 0.310       |
| Anticyclic citrullinated peptide antibody | 0.04 | 0.444 | 0.80 | 0.101 |
| Erythrocyte sedimentation rate| 0.22     | 0.152       | 0.00    | 0.488       |
| C reactive protein            | -0.26    | 0.112       | 0.03    | 0.397       |

Correlation was tested between improvement in the DAS and each laboratory test before treatment in the tocilizumab (TCZ) group and the TNF inhibitor (TNF-i) group. There was significant correlation between the DAS ratio and hemoglobin, platelet count, aspartate aminotransferase, alanine aminotransferase, and iron in the TCZ group. The results were not similar in the TNF-i group, with the exception of correlation between the DAS ratio and iron group (R = -0.60, p = 0.001), whereas there was no significant correlation in the TNF-i group (R = 0.14, p = 0.14).

**Usefulness of the predictive score in the second set of patients**

The above verification test was thought to be insufficient because it was based on a small sample size, and the patients used in the test were the same as those used to develop the scoring system. To overcome these problems, we analyzed a second set of patients.

Therefore, a validation study was performed using the clinical data of an additional 228 patients from five hospitals. Although there were differences in the tender joint count and ESR between the TCZ and TNF-i groups, there were no significant differences between the TCZ and TNF-i groups in other clinical variables, including the DAS-ESR (Table 1). The prior rates of good response in the TCZ and TNF-i groups were 57.4% and 49.5% (p = 0.24), respectively, and the rates of non-response were 12.4% and 20.2% (p = 0.11), respectively; these data were comparable to previously reported data [18, 19]. Then, the predictive scores were calculated using the patients’ laboratory tests at baseline, and the correlation between the score and the actual efficacy of TCZ or the TNF-i was examined. To verify the universality of the scoring system, all patients were included in this analysis even though some patients had liver or renal dysfunction.

There was significant correlation between the score and the DAS ratio in the TCZ group (R = -0.27, p = 0.001), whereas no significant correlation was observed in the TNF-i group (R = 0.04, p = 0.36). If the score was 2 or more (48.1% of the TCZ group and 49.5% of the TNF-i group), the rates of good response in the TCZ or TNF-i group were 66.1% and 46.9% (p = 0.04), respectively, and the rates of non-response were 3.2% and 22.4% (p = 0.001), respectively; these results were especially true if the score was 3 or more (24.8% of the TCZ group and 29.3% of the TNF-i group), in which case the rates of good response in the TCZ and TNF-i groups were 75.0% and 37.9% (p = 0.003), respectively, and the rates of non-response were 3.1% and 27.6% (p = 0.004), respectively (Fig. 3). In contrast, if the score was 1 or less (51.9% of the TCZ group and 50.5% of the TNF-i group), the rates of good response in the TCZ or TNF-i group were 66.1% and 46.9% (p = 0.004), respectively; these results were especially true if the score was 3 or more (24.8% of the TCZ group and 29.3% of the TNF-i group), in which case the rates of good response in the TCZ and TNF-i groups were 75.0% and 37.9% (p = 0.003), respectively, and the rates of non-response were 3.1% and 27.6% (p = 0.004), respectively (Fig. 3). In contrast, if the score was 1 or less (51.9% of the TCZ group and 50.5% of the TNF-i group), the rates of good response in the TCZ or TNF-i group were 66.1% and 46.9% (p = 0.003), respectively, and the rates of non-response were 3.1% and 27.6% (p = 0.004), respectively (Fig. 3).

**Discussion**

Currently, several types of bDMARDs are available; however, there are no guidelines on the appropriate treatment for individual RA patients according to the treatment mode of action, although there are some suggestions with
respect to drug safety [20]. Therefore, TNF-inhibitors, TCZ, and ABT are treated in the same way in recent disease management recommendations [11, 12]. On the other hand, many studies focusing on switching bDMARDs showed that switching to a bDMARD with a different mode of action may be more efficacious than switching to one targeting the same molecule [15, 16], suggesting that the dominant inflammatory cytokine that should be targeted may be different in each RA patient. However, several studies have failed to identify the dominant cytokine in a specific individual with RA [21]. In this study, we found that the relative mRNA levels of IL-6 and TNF-α were inversely correlated in blood samples from 45 newly diagnosed RA patients. As the half-life of mRNA is known to be five times shorter than for proteins [22], it is possible that evaluation of the relative expression level of mRNAs may reveal timely power-balance between IL-6 and TNF-α in RA. It may not be universal in each clinical situation, because the blood samples were drawn from newly diagnosed patients before any therapeutic intervention. However, it is still possible that it might be one of the explanations for the better efficacy of TCZ after inadequate response to TNF-i in some patients. The idea led us to the following study to find key laboratory indices that may reflect the power-balance between IL-6 and TNF-α in RA.

![Figure 2](image1.png)

**Fig. 2** Verification test of the scoring system in 86 patients from Iizuka Hospital. Patients with 2 or more points had a significantly increased rate of good response and a lower rate of non-response to tocilizumab (TCZ) treatment compared with TNF inhibitor (TNF-i) treatment. This tendency became remarkable in patients with 3 or more points. In contrast, patients with 1 or fewer points had a significantly increased rate of good response to TNF-i treatment compared with TCZ treatment. N.S. not significant

![Figure 3](image2.png)

**Fig. 3** Validation of the scoring system in the second set of 228 patients from five hospitals. There were no significant differences between the prior rates of good response or non-response in the tocilizumab (TCZ) and TNF inhibitor (TNF-i) groups. Patients with a score of 2 or more points (48.1% of the TCZ group and 49.5% of the TNF-i group) had a significantly higher rate of good response and a lower rate of non-response to TCZ treatment compared with TNF-i treatment. This tendency became remarkable in patients with 3 or more points (24.8% of the TCZ group and 29.3% of the TNF-i group). In contrast, if the score was 1 or less (51.9% of the TCZ group and 50.5% of the TNF-i group), a TNF-i may be preferable because a higher rate of good response and a lower rate of non-response were observed in the TNF-i group compared with the TCZ group, although these differences were not significant: *p < 0.05, **p < 0.01. N.S. not significant
Then, we found the values of Plt, iron, Hb, AST, and ALT were significantly correlated with the efficacy of TCZ treatment, and these correlations may reflect the predominant cytokine in RA pathogenesis, as described subsequently. For example, inflammatory thrombocytopoiesis is a well-known phenomenon, and it is dependent on hepatic thrombopoietin (TPO) production stimulated by IL-6 [23, 24]. The TPO produced mediates proliferative and anti-apoptotic signals via the janus kinase (JAK) and signal transducer and activator of the transcription (STAT) pathway by binding to the cellular homolog of the myeloproliferative leukemia virus oncogene (c-MPL, CD110) receptors on the surface of megakaryocytes, leading to megakaryocyte proliferation and thrombocytopoiesis [25, 26]. Moreover, it was reported that administration of IL-6 to humans is associated with an increase in circulating platelet counts [27, 28].

IL-6 is also known to induce inflammatory anemia by the production of hepcidin. Hepcidin is a peptide hormone synthesized mainly by hepatocytes and secreted in the plasma [29]. It acts as a negative iron regulator that inhibits iron absorption from the duodenum and iron release from macrophages, leading to multiple iron metabolism disorders, including iron deficiency anemia [30, 31]. IL-6 activates the JAK/STAT signaling pathway, which activates the hepcidin promoter [31, 32]. In contrast, hepcidin production is not stimulated by TNF-α [33].

It is also a known fact that IL-6 has a hepatoprotective effect. For example, IL-6 promotes hepatic survival in a variety of liver injury models, including Fas-mediated injury and toxic damage [34–36]. It has also been shown that IL-6 is essential for liver regeneration after partial hepatectomy [37, 38]. This hepatoprotective effect of IL-6 is mediated by gp130 and JAKs, leading to the activation of STATs, which mediates anti-apoptotic and anti-necrotic signals to hepatocytes [39–42]. In addition, IL-6 is associated with liver regeneration via a mitogen-activated protein kinase (MAPK) pathway, which promotes hepatocyte proliferation [42, 43]. Moreover, it was also reported that liver regeneration was mediated by platelets [44], the production of which is promoted by IL-6 stimuli as described. Thus, IL-6 promotes hepatoprotection by various pathways. In contrast, TNF-α is a well-known, predominant mediator of hepatocyte apoptosis and liver injury by promoting caspase-8 activation and the mitochondrial death pathway via c-Jun N-terminal kinase 2 (JNK2) [45–47]. Actually in the drug information sheets, mild increased serum AST and ALT was common after TCZ treatment (≤22% for AST, ≤36% for ALT), while it was uncommon after TNF-i treatment (generally ≤5%).

While Plt, Hb, AST, and ALT were correlated with TCZ efficacy, it was an interesting finding that C-reactive protein (CRP) was not correlated with the efficacy of TCZ, and this tendency was similar in the additional 228 patients (data not shown). Recently, it was reported that baseline serum concentration of CRP might not be predictive of clinical outcomes after TCZ treatment [21]. Although the reasons for this phenomenon are unclear, such acute inflammatory markers might not be suitable for prediction because of their dispersion.

In this study, higher Plt and lower Hb, AST, and ALT levels were associated with better TCZ efficacy, and these results may be due to the aforementioned physiological functions of IL-6. Because these mechanisms are unique to IL-6, each value of Plt, Hb, AST, and ALT may reflect the cytokine balance of IL-6 and TNF-α. Recently, the efficacy of alternative IL-6 inhibitors other than TCZ has been reported [48–50]. Our scoring system was developed with the result of the efficacy of TCZ; however, the aforementioned four items depend on the physiological function of IL-6 in general, so the efficacy of other IL-6 inhibitors may be predictable using our scoring system.

A verification test of the scoring system based on the original 98 patients and an additional 228 patients revealed that patients scoring 2 or more points had a significantly higher rate of good response and a lower rate of no response to TCZ compared with a TNF-i, and this tendency became more obvious if the score was 3 or more. These results suggest TCZ could have greater efficacy in patients with a score of 2 or more (approximately 50% of all patients), and especially those with a score of 3 or more (approximately 25% of all patients), compared to those with a score less than 2. These “TCZ-sensitive” patients could be distinguished in a very simple way using our scoring system, which is easily calculated using common laboratory findings.

This study has two limitations. First, it had a relatively small sample size. It would be better to have a large sample size to develop this type of scoring system. To overcome this disadvantage, we analyzed a second set of patients. Second, this was a retrospective study, and it was difficult to secure an adequate “wash-out” period when the treatment was switched from other bDMARDs. If the score was applied after an adequate wash-out period, it is possible that the predictive value of the scoring system might be more accurate. The execution of a prospective study is desirable in the future.

Conclusion
The gene expression analysis of newly diagnosed RA patients showed there were groups of patients with over-expression of either IL-6 or TNF-α. In this study, a scoring system was developed to predict the efficacy of IL-6 inhibitor based on common laboratory tests that may reflect the dominant inflammatory cytokine. The validation study suggested that this scoring system was
helpful for identifying a better treatment at the time of the selection of either an IL-6 or a TNF inhibitor.

Abbreviations
ABT: Abatacept; ADA: Adalimumab; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BDMARD: Biological disease-modifying anti-rheumatic drug; c-MPL: Cellular homolog of the myeloproliferative leukemia virus oncogene; CRP: C-reactive protein; CZP: Certolizumab pegol; DAS: Disease activity score; ESR: Erythrocyte sedimentation rate; ETN: Etanercept; EULAR: European League Against Rheumatism; GLM: Golimumab; Hb: Hemoglobin; IFX: Infliximab; IL: Interleukin; JAK: Janus kinase; JNK: c-Jun N-terminal kinase; MAPK: Mitogen-activated protein kinase; NPV: Negative predictive value; Plt: Platelet count; PPV: Positive predictive value; RA: Rheumatoid arthritis; ROC: Receiver operating characteristic; STAT: Signal transducer and activator of transcription; TCZ: Tocilizumab; TNF: Tumor necrosis factor; TPO: Thrombopoietin

Acknowledgements
We would like to thank all the RA patients who participated in this study. We also acknowledge the support of clinical staff in Kyushu University Hospital, Nagasaki University Hospital, Sasebo Chuo Hospital, Japanese Red Cross Okayama Hospital, and Iizuka Hospital.

Funding
This study was supported in part by Health Labor Sciences Research Grant of Japan (15ek0101004h0003).

Authors’ contributions
JN analyzed the data, performed the statistical analysis and drafted the manuscript. YK designed the study, contributed to acquisition of the clinical data, analysis and interpretation of the data, and critically reviewed the manuscript. HT contributed to analysis and interpretation of the data, and critically reviewed the manuscript. AK, YU, TH, SN, AU, and TO contributed to acquisition of clinical data and helped to draft the manuscript. MA and KA contributed to data interpretation and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the ethics committee of Kyushu University Hospital, Nagasaki University Hospital, Sasebo-chuo Hospital, Japanese Red Cross Okayama Hospital, and Iizuka Hospital, and the principles of the Helsinki Declaration were followed throughout the study. The gene expression study in 45 newly diagnosed RA patients was also approved by the ethics committee of Iizuka Hospital and was performed in accordance with the “Ethical Guidelines for Human Genome/Gene Research” published by the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT). Informed consent was obtained from all participants.

Consent for publication
Not applicable.

Competing interests
This author has received speaking fees from Chugai, BMS, Takeda, Ono, Mitsubishi Tanabe, Abbvie, Ayumi, and Nihon, and research funding from Eli-Lilly, Astellas, Daiichi Sankyo, and Mochida. AK has received speaking fees from Chugai, Abbvie, Eisai, Mitsubishi Tanabe, Pfizer, Jansen, Takeda, and Astellas, and research funding from Chugai, Abbvie, Eisai, Mitsubishi Tanabe, Pfizer, Jansen, Takeda, and Astellas. HT has received speaking fees from Astellas, Asahi-Kasei, Jansen, Santen, Mitsubishi Tanabe, Nipponkayaku, Thermo Fisher diagnostics, Eisai, Eli-Lilly, Kissei, Takeda, Daiichi Sankyo, BMS, Chugai, Pfizer, and Abbvie, and research funding from Mitsubishi Tanabe, Eisai, Takeda, Daiichi Sankyo, Nipponkayaku, Teijin, Eli Lilly, Abbvie, and Chugai. TH has received speaking fees from Mitsubishi Tanabe, Chugai, Abbvie, Astellas, BMS, Takeda, Jansen, Pfizer, and Actelion, and research funding from Mitsubishi Tanabe, Chugai, Astellas, BMS, Takeda, Eli Lilly, CSL Behring, Asahi-Kasei, Santen, Teijin, and Daiichi Sankyo. All other authors have declared no competing interest.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Medicine and Biostystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan. 2Department of Rheumatology, Shin-Kokura Hospital, Kitakyushu 803-8505, Japan. 3Department of Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan. 4Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo 857-1195, Japan. 5Department of Rheumatology, Shin-Kokura Hospital, Kitakyushu 803-8505, Japan. 6Department of Internal Medicine and Clinical Immunology, Kyushu University Beppu Hospital, Beppu 874-0838, Japan. 7Center for Rheumatic Diseases, Iizuka Hospital, Iizuka 820-8505, Japan.

Received: 26 September 2016 Accepted: 17 July 2017
Published online: 11 August 2017

References
1. Harris Jr ED. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990;322(18):1277–89.
2. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katinski P, Brennan FM, Walker J, Bijl H, Ghayeb J, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36(12):1681–90.
3. Klasiesko L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675–81.
4. Breedveld FC, Weisman MH, Kavanagh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37.
5. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, et al: Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210–21.
6. Choi EY, Isenberg DA, Garwood T, Fawson S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002;46(12):3143–50.
7. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(6):1761–9.
8. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009;36(6):1118–25.
9. Genoves MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114–23.
10. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanagh A, Racevicius AJ, van Vollenhoven RF, Li NF, Agarwal S, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase II randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(6):1390–400.
11. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.
30. Ganz T, Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783–8.

31. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Too to tango: regulation of mammalian iron metabolism. Cell. 2010;142(1):24–38.

32. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108(9):3204–9.

33. Nemeth E, Valare EV, Trento M, Schiller G, Lichtenstein A, Ganz T. Hecpidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7):2461–3.

34. Kovalikov K, DeAngelis RA, Li W, Furth EE, Ciliberto G, Taub R. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology. 2000;31(1):149–59.

35. Kovalikov K, Li W, DeAngelis R, Greenbaum LE, Ciliberto G, Taub R. Interleukin-6 protects against Fas-mediated liver injury by establishing a critical level of anti-apoptotic hepatic proteins FLP, Bcl-2, and Bcl-xL. J Biol Chem. 2001;276(28):26603–10.

36. James LP, Lamps LW, McCullough S, Hinson JA. Interleukin 6 and hepatocyte regeneration in acetaminophen toxicity in the mouse. Biochim Biophys Res Commun. 2003;304(4):857–63.

37. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R. Liver failure and defective hepatic hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996;274(5291):1370–83.

38. Blendenbacher A, Wang X, Langer I, Savino R, Terracciano L, Heim MH. Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology. 2003;38(3):674–82.

39. Haga S, Terui K, Zhang HQ, Enosawa S, Ogawa W, Itohe H, Okuyama T, Takeda K, Akita S, Ongko T, et al. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest. 2003;112(7):989–98.

40. Klein C, Wustefeld T, Assmus U, Roskams T, Rose-John S, Muller MP, Ernst M, Trautwein C. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest. 2005;115(4):860–9.

41. Plum W, Tschaharganeh DF, Kroy DC, Corsten E, Erschfeld S, Diessens U, Wasmuth H, Trautwein C, Streetz KL. Lack of glycoprotein 130/signal transducer and activator of transcription 3-mediated signaling in hepatocytes enhances chronic liver injury and fibrosis progression in a model of sclerosing cholangitis. Am J Pathol. 2010;176(5):2236–46.

42. Taub R. Hepatoprotection via the IL-6Stat3 pathway. J Clin Invest. 2003;112(7):798–80.

43. Li W, Liang X, Kellendonk C, Poli V, Taub R. STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem. 2002;277(32):28411–7.

44. Lesurmel M, Graf R, Alet B, Walther DJ, Tian Y, Jochum W, Gachet C, Bader M, Clavien PA. Platelet-derived serotonin mediates liver regeneration. Science. 2006;312(5770):104–7.

45. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, Satoh S, Niwa M, Senoh H, Fujikawa H, H. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin-6. J Exp Med. 1994;179(5):1529–37.

46. Wang Y, Singh R, Leitkowski JH, Rigoli RM, CZaja MI. Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J Biol Chem. 2006;281(22):15258–67.

47. Chen X, Ding WX, Ni HM, Gao W, Shi YH, Gambotto LA, Fan J, Beg AA, Yin XM. Bid-independent mitochondrial activation in tumor necrosis factor alpha-induced apoptosis and liver injury. Mol Cell Biol. 2007;27(2):541–53.

48. Genovesi MC, Fleischmann R, Kwizik AJ, Reil-Balakirski M, Martincovo R, Fiore S, Rohane P, van Hoogstraten H, Garg A, Fan C, et al. Sulfurubam plus metothrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424–37.

49. Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Ha S, Bursukam, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73(9):1616–25.

50. Mease P, Strand V, Shalambereze L, Dimic A, Raskina T, Xu LA, Yu L, Smith JA. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis. 2012;71(7):1183–9.